Trial · NCT07139405
TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy
NCT07139405, Phase 2, Not yet recruiting, Myopharm Limited
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy. Trials, record NCT07139405. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07139405
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy
- NCT number
- NCT07139405
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 48 participants, estimated
- Lead sponsor
- Myopharm Limited
- Conditions
- Type 2 Diabetes (T2DM)
- Interventions
- Metformin XR, Celecoxib, Valsartan
- First posted
- 2025-08-24
- Last updated
- 2026-07-08
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and severity of treatment-emergent adverse events and changes in clinical safety assessments through Week 16. | 16 weeks | |
| Secondary | Change in HbA1c | 16 weeks | |
| Secondary | Proportion achieving HbA1c <7.0% | 16 weeks | |
| Secondary | Change in fasting plasma glucose | 16 weeks | |
| Secondary | Change in body weight | 16 weeks | |
| Secondary | Change from Baseline to Week 16 in Total Body Fat Percentage Measured by Dual-energy X-ray Absorptiometry (DEXA) | 16 weeks | Change in total body fat (%) measured using whole-body dual-energy X-ray absorptiometry (DEXA). |
| Secondary | Requirement for rescue therapy | 16 weeks | |
| Secondary | Maximum Plasma Concentration (Cmax) of Study Treatment Components | 16 weeks | Plasma maximum observed concentration (Cmax) |
| Secondary | Time to Maximum Plasma Concentration (Tmax) of Study Treatment Components | 16 weeks | Time to maximum observed plasma concentration (Tmax) |
| Secondary | Area Under the Plasma Concentration-Time Curve (AUC) of Study Treatment Components | 16 weeks | Plasma area under the concentration-time curve (AUC) |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07139405
GET https://conductscience.org/api/trials/v1/NCT07139405/registered